GLP-1s
US$ 23.88
retatrutide phase 2 trial type 2 diabetes weight loss 2024 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished Perceived benefits of treatment for
Description
Thats where the right supplements come in
For one study (SURPASS-2), we used data both from the journal publication [25] and from a conference abstract [24]
Consult with qualified professionals for advice specific to your situation
It doesnt mean everyone has that experience, but it does suggest their consistency may have slipped recently
Dose adjustment for maintenance: After reaching goal weight, some users reduce from 10-12mg to 6-8mg weekly while maintaining results
